Search Browse Earnings

RenovoRx, Inc. — SlamSEC

RenovoRx, Inc.

Nasdaq:RNXT

Pharmaceutical Preparations·MOUNTAIN VIEW, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$43,000

FY 2024

Adj. EBITDA

—

Net Income

-$10.2M

-23795.3% margin

FY 2024

EPS (Diluted)

-$0.99

FY 2024

Stock Price

$0.81

+2.5%

2026-03-10

52W Range

$0.70 – $1.45

P/E Ratio

-0.8x

Market Cap

$29.7M

Cash

$1.2M

FY 2024

Total Debt

—

Net Cash

$1.2M

FY 2024

Enterprise Value

$28.5M

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

CEO

Bagai Shaun